Home › Chronic Lymphocytic Leukemia › NCT06151730

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study

Who can join

All ages · All sexes

Inclusion Criteria:

* Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up

Exclusion Criteria:

* Patients with known central nervous system (CNS) involvement of their B-cell malignancy

About the study

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

What is being tested

• Non-Interventional Study (other)

Sponsor: Mayo Clinic · Participants: 100 · Started: Jan 5, 2024

Contact the study team

• Clinical Trials Referral Office · Phone: 855-776-0015

Official record on ClinicalTrials.gov — NCT06151730

Locations in the U.S.

Conditions

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Waldenstrom Macroglobulinemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.